Mehta Pankaj D, Pirttila Tuula
Institute for Basic Research, Staten Island, NY 10314, USA.
Neurodegener Dis. 2005;2(5):242-5. doi: 10.1159/000090363.
We quantitated amyloid beta peptide (A beta) 38, A beta40 and A beta42 levels in matched CSF and plasma from Alzheimer disease (AD) patients and controls. CSF A beta38 and A beta40 levels were similar in AD patients and in controls; however, they were higher in controls with APOE upsilon4 allele than those without. CSF A beta42 levels were lower in AD patients than in controls. The CSF A beta38/42 ratio was higher in AD patients than controls, consistent with the previously reported higher A beta40/42 ratio. A beta38, A beta40 and A beta42 levels in plasma were similar in AD patients and in controls and showed no relationship to levels in CSF. Our findings suggest that the increased CSF A beta38/42 ratio found in AD patients is derived entirely from reduction of CSF A beta42 levels.
我们对阿尔茨海默病（AD）患者及对照者配对的脑脊液（CSF）和血浆中的β淀粉样肽（Aβ）38、Aβ40和Aβ42水平进行了定量分析。AD患者和对照者的脑脊液Aβ38和Aβ40水平相似；然而，携带APOE ε4等位基因的对照者的这两项水平高于未携带该等位基因的对照者。AD患者的脑脊液Aβ42水平低于对照者。AD患者的脑脊液Aβ38/42比值高于对照者，这与之前报道的较高的Aβ40/42比值一致。AD患者和对照者血浆中的Aβ38、Aβ40和Aβ42水平相似，且与脑脊液中的水平无关。我们的研究结果表明，AD患者脑脊液中升高的Aβ38/42比值完全源于脑脊液Aβ42水平的降低。
